| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $16 to...
JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $13 to ...
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $13 to $14.
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises the price target from $15 to ...